Data Sheet (Cat.No.T62927)

TargetMol

ZYF0033

Chemical Properties



CAS No. : 2380300-79-6

Formula: C26H30N4O2S

Molecular Weight: 462.61

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	ZYF0033 is an orally effective small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1) that inhibits the phosphorylation of MBP proteins.HPK1-IN-22 promotes anticancer immune responses by decreasing the phosphorylation of SLP76 (serine 76), and has the potential to inhibit tumor growth and mediate immune responses.
Targets(IC50)	Others,MAPK
In vitro	ZYF0033 (HPK1-IN-22) (100 nM, 24 h) reduces the phosphorylation of SLP76 (serine 376) in T cells, leading to HPK1 inhibition and increasing the proliferation of CD4+ and CD8+ T cells and the secretion of IFN-γ. [1]

Solubility Information

Solubility	DMSO: 80 mg/mL (172.93 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (7.13 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1616 mL	10.8082 mL	21.6165 mL
5 mM	0.4323 mL	2.1616 mL	4.3233 mL
10 mM	0.2162 mL	1.0808 mL	2.1616 mL
50 mM	0.0432 mL	0.2162 mL	0.4323 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Si J, et al. Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. Cancer Cell. 2020 Oct 12;38(4):551-566.e11.
Jingwen Si, et al. Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. Cancer Cell. 2020 Oct 12;38(4):551-566.e11.